Chordate Medical selects analysis firm Kalqyl for analysis and ongoing monitoring

Chordate Medical has signed an agreement with Kalqyl for report monitoring and commissioned analyses. The collaboration includes independent monitoring of the company and its market potential with a valuation scenario from a potential buyer's perspective.

“Our ambition is for shareholders and stakeholders to have access to a relevant analysis of the company and the market potential that aligns with the company's strategy. Kalqyl's previous work demonstrates a deep understanding of the market and well-founded analyses of listed companies," says Anders Weilandt, CEO of Chordate Medical.

“Chordate is an exciting company. Starting from the perspective of a potential buyer of the company is a new way for us to do a company analysis, but at the same time, the most logical starting point," says David Uhrner, CEO of Kalqyl.

About Kalqyl
Kalqyl is an analysis company with a rapidly growing platform and a unique reach among Nordic investors. Kalqyl's analyses help companies clarify their business concepts and enable investors to better understand their operations. Kalqyl is a wholly owned subsidiary of Spotlight Group, acquired in August 2021.

Datum 2023-10-12, kl 14:20
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!